Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients.

Based on breast cancer families with multiple and/or early-onset cases, estimates of the lifetime risk of breast cancer in carriers of BRCA1 or BRCA2 mutations may be as high as 85%. The risk for individuals not selected for family history or other risk factors is uncertain. We determined the frequency of the common BRCA1 (185delAG and 5382insC) and BRCA2 (6174delT) mutations in a series of 268 anonymous Ashkenazi Jewish women with breast cancer, regardless of family history or age at onset. DNA was analyzed for the three mutations by allele-specific oligonucleotide hybridization. Eight patients (3.0%, 95% confidence interval [CI] 1.5%-5.8%) were heterozygous for the 185delAG mutation, two (0.75%, 95% CI 0.20-2.7) for the 5382insC mutation, and eight (3.0%, 95% CI 1.5-5.8) for the 6174delT mutation. The lifetime risk for breast cancer in Ashkenazi Jewish carriers of the BRCA1 185delAG or BRCA2 6174delT mutations was calculated to be 36%, approximately three times the overall risk for the general population (relative risk 2.9, 95% CI 1.5-5.8). For the 5382insC mutation, because of the low number of carriers found, further studies are necessary. The results differ markedly from previous estimates based on high-risk breast cancer families and are consistent with lower estimates derived from a recent population-based study in the Baltimore area. Thus, presymptomatic screening and counseling for these common mutations in Ashkenazi Jewish women not selected for family history of breast cancer should be reconsidered until the risk associated with these mutations is firmly established, especially since early diagnostic and preventive-treatment modalities are limited.

[1]  J. Rommens,et al.  The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds , 1996, Nature Genetics.

[2]  T. Rebbeck,et al.  Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. , 1995, JAMA.

[3]  Y. Bignon,et al.  Histoprognostic grade in tumours from families with hereditary predisposition to breast cancer , 1995, The Lancet.

[4]  D. B. Berman,et al.  Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families , 1996, Nature Medicine.

[5]  K Offit,et al.  Germline BRCA1 185delAG mutations in Jewish women with breast cancer , 1996, The Lancet.

[6]  Kenneth Offit,et al.  The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1% , 1996, Nature Genetics.

[7]  Patrick Dowd,et al.  Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families , 1994, Nature Genetics.

[8]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[9]  P. Tonin,et al.  BRCA1 mutations in Ashkenazi Jewish women. , 1995, American journal of human genetics.

[10]  W. Willett,et al.  Jewish religion and risk of breast cancer , 1996, The Lancet.

[11]  N Risch,et al.  Genetic analysis of breast cancer in the cancer and steroid hormone study. , 1991, American journal of human genetics.

[12]  K Offit,et al.  BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. , 1997, JAMA.

[13]  M. Stratton,et al.  Recent advances in understanding of genetic susceptibility to breast cancer. , 1996, Human molecular genetics.

[14]  G M Lenoir,et al.  Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage , 1996, Cancer.

[15]  M. King,et al.  Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. , 1995, American journal of human genetics.

[16]  J. Rommens,et al.  Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families , 1994, Nature Genetics.

[17]  Kenneth Offit,et al.  Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer , 1996, Nature Genetics.

[18]  S. Seal,et al.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. , 1994, Science.

[19]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[20]  R. Sepp,et al.  Rapid techniques for DNA extraction from routinely processed archival tissue for use in PCR. , 1994, Journal of clinical pathology.

[21]  I. Lerer,et al.  The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. , 1997, American journal of human genetics.

[22]  Alfred A. Boyd,et al.  Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 , 1996, Nature Genetics.

[23]  P. Wingo,et al.  Cancer statistics, 1997 , 1997, CA: a cancer journal for clinicians.

[24]  F. Collins,et al.  The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals , 1995, Nature Genetics.

[25]  D. Birnbaum,et al.  Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. , 1996, Cancer research.

[26]  Barbara L. Smith,et al.  Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. , 1996, The New England journal of medicine.

[27]  K. Klinger,et al.  A simplified procedure for developing multiplex PCRs. , 1995, Genome research.

[28]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[29]  B. Ponder,et al.  Rapid detection of regionally clustered germ-line BRCA1 mutations by multiplex heteroduplex analysis. UKCCCR Familial Ovarian Cancer Study Group. , 1996, American journal of human genetics.